Sprout Pharmaceuticals Confirms Resubmission To FDA Of Flibanserin For Treatment Of Pre-Menopausal Hypoactive Sexual Desire Disorder

Phase 3 clinical trial, including >1,000 patients, showed positive results Agency action expected before end of 2013 RALEIGH, N.C., June 26, 2013 /PRNewswire/ -- Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application (NDA) for flibanserin earlier this year and expects US Food and Drug Agency (FDA) action before the end of 2013.  If approved, flibanserin would be the first FDA approved treatment for HSDD in pre-menopausal women. HSDD, a form of female...